Results 101 to 110 of about 14,439 (224)

Biosimilars in the management of neutropenia: focus on filgrastim

open access: yes, 2016
Désirée Caselli,1 Simone Cesaro,2 Maurizio Aricò1 1Medical Department, Pediatric Unit, Azienda Sanitaria Provinciale Ragusa, Ragusa, 2Department of Pediatrics, Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria ...
Aricò M, Caselli D, Cesaro S
core  

Biosimilars Have Arrived: Rituximab

open access: yes, 2018
A biosimilar is a biologic product that is highly similar to a licensed biologic (“originator”) such that there are no clinically meaningful differences in safety, purity, or potency between the biosimilar and the originator.
K. Lea Sewell   +2 more
core   +1 more source

Proteomic analysis in hidradenitis suppurativa reveals systemic inflammation in all disease stages

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Proteomic profiling reveals systemic inflammation in patients with hidradenitis suppurativa, even in early disease. Distinct mediators (e.g. TGF‐α, OSM, HGF) are elevated early, whereas others correlate with clinical severity (e.g. IL‐6, VEGF‐A, IL‐17A) or disease duration (e.g.
Lotta Sandelin Francke   +5 more
wiley   +1 more source

Policies for biosimilar uptake in Europe: An overview.

open access: yesPLoS ONE, 2017
BackgroundAcross European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergences in savings all over Europe.ObjectivesThe aim of this article is to provide an overview of different initiatives ...
Evelien Moorkens   +33 more
doaj   +1 more source

Biosimilars in pediatrics

open access: yesArchivos Argentinos de Pediatria
Biosimilars are highly similar versions of already authorized biological drugs. A notable benefit of these is their significantly lower price compared to innovator drugs, which frees up healthcare resources and improves affordability. Leading regulatory agencies approve biosimilars after rigorous comparability studies, ensuring that there are no ...
Paulo, Cáceres Guido   +1 more
openaire   +2 more sources

Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
No evidence of an increased risk of incident cancer or KC was observed with biologic versus non‐biologic systemic therapies or across the biologic classes evaluated. Abstract Background There are concerns that biologic therapies for psoriasis may increase cancer risk. Objectives To compare risks of (i) incident cancer excluding keratinocyte carcinomas (
Oras A. Alabas   +9 more
wiley   +1 more source

Optimising the use of unaffordability as a ground for compulsory licensing in African patent systems

open access: yesThe Journal of World Intellectual Property, EarlyView.
Abstract Although competition law has widely examined the issue of excessive pricing, its treatment within the patent law framework remains underexplored. This article examines how national patent laws structure grounds for compulsory licensing to address unaffordable pricing (under varying terminology) and analyses their structural limitations, with a
Isaac Kundakogo Kunko
wiley   +1 more source

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany

open access: yes, 2017
John Waller,1 Emma Sullivan,1 James Piercy,1 Christopher M Black,2 Sumesh Kachroo2 1Adelphi Real World, Manchester, UK; 2Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA Objectives: We examined ...
Kachroo S   +4 more
core  

Què són els medicaments biosimilars? [audiovisual]

open access: yes, 2023
Medicaments biosimilars; Medicaments biològics; UtilitzacióMedicamentos biosimilares; Medicamentos biológicos; UtilizaciónBiosimilar medicines; Biological drugs; UtilizationAquest vídeo explica què són els medicaments biosimilars, quins tipus hi ha ...

core  

What role for real-world evidence in market access of biosimilars?

open access: yesFrontiers in Pharmacology
Experience with the use of biosimilars in real-life practice provides an excellent opportunity to collect real-world evidence aimed at addressing residual uncertainties about biosimilars.
Steven Simoens   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy